European Journal of Heart Failure

European Journal of Heart Failure 2004 6(3):327-333; doi:10.1016/j.ejheart.2004.01.006

This Article Abstract FREE Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Request Permissions Disclaimer Google Scholar Articles by Galvani, M. Articles by Ottani, F. Search for Related Content PubMed PubMed Citation Articles by Galvani, M. Articles by Ottani, F. Social Bookmarking          What's this?

© 2004 European Society of Cardiology

Natriuretic peptides for risk stratification of patients with acute coronary syndromes

Marcello Galvani^*, Donatella Ferrini and Filippo Ottani

The Cardiovascular Research Unit of the Fondazione Sacco and the Department of Cardiology Ospedale G.B. Morgagni, Forlì, Italy

^* Corresponding author. Present address. Fondazione Cardiologica Sacco, Piazza F.lli Ruffini, 6, 47100, Forlì, Italy. Tel.: +39-543-33283; Fax: +39-543-31720 E-mail address: galvanim{at}tin.it

	Abstract

Top Abstract 1. Introduction 2. Natriuretic peptide release... 3. Natriuretic peptides... 4. Prognostic value of... 5. Therapeutic interventions... 6. Conclusion References

 
Natriuretic peptides (BNP and NT-proBNP) have been shown to be useful tools for risk stratification of patients with acute myocardial ischemia encompassing the whole spectrum of acute coronary syndromes (ACS), particularly for prediction of mortality. Both BNP and NT-proBNP possess several characteristics of the ideal biomarker, showing independent and incremental prognostic value above traditional clinical, electrocardiographic, and biochemical (particularly troponin) risk indicators. Specifically, in ACS patients, BNP and NT-proBNP have powerful prognostic value both in patients without a history of previous heart failure or without clinical or instrumental signs of left ventricular dysfunction on admission or during hospital stay. They can also be easily and rapidly measured in an emergency context. We have performed a meta-analysis of available studies concerning the prognostic value of natriuretic peptides. Our results show that the prognostic value of natriuretic peptides is similar: (1) both at short- and long-term; (2) when natriuretic peptides are measured at first patient contact or during hospital stay; (3) for BNP or NT-proBNP; and (4) in patients with ST elevation myocardial infarction or no ST elevation ACS. These data suggest that natriuretic peptide measurement should be integrated into routine evaluation of patients with an ACS.

Key Words: Natriuretic peptide • Acute myocardial infarction • Prognosis

Received December 29, 2003; Accepted January 14, 2004

	1. Introduction

Top Abstract 1. Introduction 2. Natriuretic peptide release... 3. Natriuretic peptides... 4. Prognostic value of... 5. Therapeutic interventions... 6. Conclusion References

 
Risk stratification of patients with acute coronary syndromes (ACS), whether with ST-elevation myocardial infarction (STEMI) or without persistent ST-elevation (NSTE-ACS), is fundamental in determining prognosis and choosing appropriate care. This improves the cost-effectiveness of patient care since evidence-based treatments (such as anti-platelet, anti-thrombotic, and revascularization therapies) can be targeted at the patients who are most likely to benefit from their use.

Risk assessment is based on the clinical history, examination findings, electrocardiographic (ECG) changes, and markers of myocardial damage, particularly cardiac troponin [1–3]. The prognostic indicators should be available at the time of initial patient evaluation, in order to maximize the potential benefit of early risk-assessment. Currently, despite careful integration of key prognostic variables, risk prediction based on clinical, electrocardiographic, and biochemical, i.e. cardiac troponin, markers is relatively inaccurate [4]. Therefore, there is still room for new prognostic indicators. For this purpose, there is emerging evidence that natriuretic peptides possess several characteristics of the ideal biomarker; in addition, rapid immunoassays have recently become available at a reasonable cost.

There are three classes of natriuretic peptides [5,6]. Both BNP and NT-proBNP have been shown to aid in the diagnosis of heart failure and to correlate with functional status among patients with CHF [7]. Levels of BNP and NT-proBNP also correlate with left ventricular dilatation, remodelling, and dysfunction, as well as heart failure and death among patients presenting with acute myocardial infarction [8,9].

A robust association between BNP or NT-proBNP and the short- and long-term risk of death across the spectrum of ACS has recently been demonstrated [10–16,23]. In some patients with ACS, elevated levels of BNP directly reflect the degree of left ventricular dysfunction resulting from acute myocardial infarction. However, the strong association between levels of BNP and NT-proBNP and mortality even among patients without myocyte necrosis (as detected by the release of cardiac troponin) indicate that the level of BNP may reflect the extent or severity of the ischemic insult, even when irreversible injury has not occurred.

In this paper we review the current evidence supporting the use of natriuretic peptides for early risk stratification of patients with ACS. For this purpose, we have combined the results of four published studies and one study published as an abstract, using meta-analysis techniques [11–14,16], in order to address some clinically relevant questions: (1) is the prognostic value of natriuretic peptides (BNP and NT-proBNP) similar both at short- and long-term?; (2) is the prognostic value similar when natriuretic peptides are measured at first patient contact or during hospital stay?; (3) is it better to measure BNP or NT-proBNP?; and (4) is the prognostic value similar in patients with STEMI or NSTE- ACS? Main characteristics of the included studies are summarized in Table 1.

View this table: [in this window] [in a new window]   Table 1 Studies on prognostic value of natriuretic peptide measurement in patients with ACS permitting a dichotomous and homogeneous approach to data analysis (based on the possibility to extract the median concentration)

 

	2. Natriuretic peptide release in acute myocardial ischemia

Top Abstract 1. Introduction 2. Natriuretic peptide release... 3. Natriuretic peptides... 4. Prognostic value of... 5. Therapeutic interventions... 6. Conclusion References

 
Elevated levels of natriuretic peptides have been detected in patients with ACS in the absence of detectable myocardial necrosis [17]. It has been demonstrated that levels of BNP increase transiently after uncomplicated coronary angioplasty in the presence of stable intra-cardiac filling pressure, as well as after exercise-induced ischemia in patients with stable coronary artery disease [8]. Together, these findings suggest that transient ischemia may induce BNP synthesis and release in proportion to the severity of myocardial ischemia. No such studies exist on ANP; furthermore, the different release kinetics and the different persistence in blood of BNP and NT-proBNP in comparison with ANP make the former a more attractive approach to risk-stratification of patients with ACS than the latter.

The mechanism of production of natriuretic peptides in myocardial ischemia is unclear. Myocardial ischemia in unstable angina may increase regional ventricular wall stretch owing to local depression of myocardial contraction. Mechanical stretch can activate the JAK/STAT pathway and may stimulate NT-proBNP secretion [18] and augment the messenger RNA expression of IL-6 and cardiotrophin 1 [19]. This common mechanism of stimulation may explain the correlation between NT-proBNP and cardiotrophin 1 in unstable angina. Alternatively, cardiotrophin 1 may directly promote myocardial transcription of BNP.

	3. Natriuretic peptides concentrations in ACS

Top Abstract 1. Introduction 2. Natriuretic peptide release... 3. Natriuretic peptides... 4. Prognostic value of... 5. Therapeutic interventions... 6. Conclusion References

 
The interpretation of early natriuretic peptide measurement in ACS patients can be difficult since levels of BNP and NT-proBNP vary considerably according to index diagnosis [20] and rise continuously during the first 24 h after the onset of ischemia [21]. It has been shown that natriuretic peptide levels are higher in patients with MI than in those with unstable angina, and in patients with STEMI than in those with NSTEMI, possibly reflecting the amount of myocardium at risk and the extent of myocardial necrosis. Concentrations increase very rapidly and steeply in the first day after the onset of myocardial ischemia, making the comparison of concentrations across different populations difficult. Finally, it must be acknowledged that BNP and NT-proBNP concentrations markedly differ by age, gender, and assay system [22].

It is therefore challenging to derive an optimal discriminatory prognostic cut-off according to these factors, possibly implying that a single cut-off level cannot be used in clinical practice. In the clinical studies, which we have taken into consideration, natriuretic peptide concentrations were reported as levels above or below the median value observed in the population under study, thus permitting a dichotomous approach to the interpretation of the results. For this reason, we have excluded studies where patients are classified according to the presence or the absence of elevations [10], and studies [7] where natriuretic peptide levels are divided into terciles.

	4. Prognostic value of natriuretic peptides in ACS

Top Abstract 1. Introduction 2. Natriuretic peptide release... 3. Natriuretic peptides... 4. Prognostic value of... 5. Therapeutic interventions... 6. Conclusion References

 
The prognostic value of BNP and NT-proBNP, measured in the sub-acute phase, on mortality of patients with an ACS has been assessed in several studies. Omland et al. [15], in a nested case-control TIMI 11B sub-study, for the first time found higher NT-proBNP levels in patients with NSTE-ACS who died early than in those who survived. De Lemos et al. [13] included 2525 patients from one of the treatment arms of the OPUS-TIMI 16 trial. BNP, measured during the first few days after the onset of ischemic symptoms, was strongly and independently predictive of mortality at 10 months. Omland et al. also evaluated ‘real world’ patients in a study primarily designed to evaluate risk indicators in ACS [14]. NT-proBNP was predictive of long-term mortality independently from Killip class, patient age, and left ventricular ejection fraction even in patients with no evidence of clinical heart failure.

The value of early measurement of natriuretic peptides has been less extensively studied. Jernberg et al. [12] measured NT-proBNP on admission in 755 patients admitted to the coronary care unit because of chest pain and no ST-segment elevation (54% with an ACS) at a median time of 6 h from the onset of symptoms. Compared to the lowest quartile, patients in the second, third and fourth quartiles had a relative risk of subsequent death of 4.2, 10.7 and 26.6, respectively. More recently, James et al. [11] measured NT-proBNP in 6809 out of 7800 ACS patients enrolled in the GUSTO-IV trial. Samples were obtained at a median of 9.5 h from symptom onset. The results of this study clearly showed that NT-proBNP was the strongest predictor of mortality, but was not an independent predictor of subsequent ischemic events. In fact, increasing quartiles of NT-proBNP were related to short- and long-term mortality that reached 1.8%, 3.9%, 7.7%, and 19.2% (P<0.001), respectively, at 1 year. Finally, we measured NT-proBNP at a median time of 3 h after symptom onset in 1756 patients with ACS [16]. The outcome measure of our study was death at 30 days, which occurred in 113 patients. The median NT-proBNP level was 353 (107 to 1357) ng/l. Compared to the lowest quartile, patients in the second, third and fourth quartiles had a relative risk of subsequent death of 2.94, 5.32, and 11.5, respectively. NT-proBNP was independently associated with death in a logistic regression model, which included clinical variables, ECG, and troponin T both in patients with and without persistent ST-segment elevation. NT-proBNP was also an independent predictor of the short-term occurrence of severe heart failure.

All these studies are concordant in indicating that BNP and NT-proBNP are independent predictors of subsequent mortality. The prognostic information of natriuretic peptide measurement is in fact additional to several key prognostic variables. In particular, BNP and NT-proBNP allow to further stratify the risk of two important patient subgroups: those without overt signs of heart failure and those without troponin elevations on admission. Secondly, although being powerful predictors of the occurrence of heart failure, natriuretic peptides are not predictors of subsequent recurrent ischemic events, particularly non-fatal myocardial infarction. This is in keeping with the pathophysiology of BNP and NT-proBNP elevations, which are not causally linked to the progression of coronary thrombosis with its attendant ischemic complications.

4.1. Short-term vs. long-term mortality
The results of our meta-analysis indicate that the prognostic value of BNP and NT-proBNP is similar both in the long-term (OR 4.31; 95% CI 3.77–4.94) and in the short-term (OR 3.38; 95% CI 2.44–4.68). This observation has important practical implications since the demonstration of a short-term prognostic value may justify research efforts directed to target specific interventions in patients with elevated natriuretic peptide levels during the acute phase of the disease (Fig. 1).

View larger version (13K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 1 Peto odds ratio (fixed model) of natriuretic peptide concentrations above the median level of the study population concerning long-term (James: 1-year, Jernberg: 40 months, Omland: 51 months, deLemos: 10 months) and short-term (Galvani: 30 days, James: 48 h) death.

 
4.2. Early sampling vs. late sampling
The results of our meta-analysis also show that the prognostic value of natriuretic peptide measurement is similar when blood is obtained at the time of first patient contact (OR 4.42; 95% CI 3.83–5.10) or in the following hours or days after admission (OR 3.51; 95% CI 2.64–4.67). The prognostic value of natriuretic peptide measurement, when performed in the sub-acute phase of STEMI, is well established. The findings of the recent studies conducted on the whole spectrum of patients with ACS expand and reinforce this observation showing that the same prognostic discriminatory capacity is obtained when measurement is obtained as soon as possible, suggesting that the adverse prognosis associated with the finding of elevated natriuretic peptide levels might be favorably influenced by immediate or, at least, early therapeutic interventions (Fig. 2).

View larger version (12K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 2 Peto odds ratio (fixed model) of natriuretic peptide concentrations above the median level of the study population in comparison with natriuretic peptide concentrations below the median concerning early sampling and late sampling. For details regarding characteristics of the included studies see Table 1. Outcome measure of comparisons is death.

 
4.3. BNP vs. NT-proBNP
Plasma concentrations of BNP and NT-proBNP are correlated. However, in patients with left ventricular dysfunction, the proportional and absolute increase of NT-proBNP exceeds that of BNP, suggesting that NT-proBNP may be a more sensitive marker of left ventricular dysfunction [24].

There is only one study which evaluated the prognostic value of BNP [13]; therefore a formal meta-analysis is not possible. In that study, the OR of death in patients with BNP levels above and below the median value of the population was 3.54 (95% CI 2.42–5.17). This value is only slightly lower than the OR ratio observed in studies with NT-proBNP (4.42; 95% CI 3.83-5.10) suggesting that both BNP and NT-proBNP can be used in clinical practice for prognostic purposes.

4.4. STEMI vs. NSTE-ACS
There were only two studies evaluating the whole spectrum of patients with ACS, thus allowing a direct comparison across patient sub-groups. In one study, blood was sampled very early; in the other study blood was obtained in the sub-acute phase. This difference was particularly pronounced in the case of patients with STEMI. It is interesting to observe that the prognostic value of natriuretic peptide measurement was remarkably similar in the two studies and across patient sub-groups. This finding suggests a role for early natriuretic peptide measurement even in patients with STEMI (Fig. 3).

View larger version (12K): [in this window] [in a new window] [Download PowerPoint slide]   Fig. 3 Peto odds ratio (fixed model) of natriuretic peptide concentrations above the median level of the study population in comparison with natriuretic peptide concentrations below the median concerning patients with ST-elevation myocardial infarction (STEMI) and no ST-elevation acute coronary syndrome (NSTE-ACS). For details regarding characteristics of the included studies see Table 1. Outcome measure of comparisons is death.

 

	5. Therapeutic interventions according to natriuretic peptide levels

Top Abstract 1. Introduction 2. Natriuretic peptide release... 3. Natriuretic peptides... 4. Prognostic value of... 5. Therapeutic interventions... 6. Conclusion References

 
In patients with NSTE-ACS, two studies have evaluated whether an invasive strategy is particularly effective in patients with elevated BNP and NT-proBNP levels, reporting apparently conflicting results.

Morrow et al. [10] evaluated BNP at baseline in 1676 patients randomized to early invasive vs. conservative management in the TACTICS-TIMI 18 trial. Patients with elevated BNP (80 pg/ml; n=320) were at higher risk of death at seven days (2.5% vs. 0.7%, P<0.006) and 6 months (8.4% vs. 1.8%, P<0.0001). No difference, however, was observed in the effect of invasive vs. conservative management when stratified by baseline levels of BNP (P_{for interaction}=0.6). Patients with BNP levels 80 pg/ml had a 6 month mortality rate of 7.9% when assigned to an invasive strategy, and a mortality if 9.0% when assigned to a conservative approach (OR 0.87; 95% CI 0.4–1.9).

Jernberg et al. [7] examined whether measurements of NT-proBNP, in addition to troponin T and interleukin-6, improved the ability to identify high-risk patients who benefit from an early invasive strategy in 2019 patients randomized to an invasive or non-invasive strategy in the FRISC-II trial. Patients were followed up for 2 years to determine death and MI. Patients in the third NT-proBNP tertile had a 4.1-fold (95% CI 2.4–7.2) and 3.5-fold (95% CI 1.8–6.8) increased mortality in the non-invasive and invasive groups, respectively. In patients with increased levels of both NT-proBNP and IL-6, an early invasive strategy reduced mortality by 7.3% (risk ratio 0.46, 95% CI 0.21–1.00). In patients with lower NT-proBNP or IL-6 levels, the mortality was not reduced. Reasons for possible differences between the two studies are not completely clear [25]. One possible reason is that NT-proBNP elevations, being more pronounced than those of BNP, identify a larger proportion of patients with elevations thus permitting a more balanced comparison between patients with and without elevations. Furthermore, in contrast with FRISC-II, the invasive approach did not reduce mortality in TACTICS-TIMI 18; this precludes detecting mortality differences in the subset of patients with BNP elevations. Nevertheless, the non-significant 13% relative reduction in 6-month mortality seen in TACTICS-TIMI-18 patients with BNP levels of 80 pg/ml (odds ratio 0.87, 95% CI 0.4–1.9) is not inconsistent with the 41% relative reduction in 2-year mortality seen in patients in the highest tertile of NT-proBNP levels in FRISC-II.

No data exist about the preferred therapeutic approach to patients with elevated natriuretic peptide levels in STEMI.

	6. Conclusion

Top Abstract 1. Introduction 2. Natriuretic peptide release... 3. Natriuretic peptides... 4. Prognostic value of... 5. Therapeutic interventions... 6. Conclusion References

 
Natriuretic peptide measurement is a powerful tool to assess the risk of death in patients with ACS. The information provided by this biomarker is incremental to that offered by conventional risk markers. Given the ability to capture the risk of troponin negative patients, it offers promise to integrate troponin as first-line biomarker particularly when blood is sampled very early after the onset of ischemia. There are, however, pitfalls to its immediate implementation in clinical practice related to the application of decisional cut-off levels (which, in our opinion, should take into consideration age, sex, index diagnosis and time from symptom onset), and the identification of specific therapeutic approaches to patients with elevated natriuretic peptide levels.

	References

Top Abstract 1. Introduction 2. Natriuretic peptide release... 3. Natriuretic peptides... 4. Prognostic value of... 5. Therapeutic interventions... 6. Conclusion References

 

1. Bertrand M.E., Simoons M.L., Fox K.A., Wallentin L.C., Hamm C.W., McFadden E., et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J (2002) 23:1809–1840.[Free Full Text]
2. Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol (2002) 40:1366–1374.[Free Full Text]
3. Stubbs P., Collinson P., Moseley D., Greenwood T., Noble M. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation (1996) 94:1291–1297.[Abstract/Free Full Text]
4. Singh M., Reeder G.S., Jacobsen S.J., Weston S., Killian J., Roger V.L. Scores for post-myocardial infarction risk stratification in the community. Circulation (2002) 106:2309–2314.[Abstract/Free Full Text]
5. de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci (1981) 28:89–94.[CrossRef][Web of Science][Medline]
6. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature (1988) 332:78–81.[CrossRef][Medline]
7. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med (2002) 347:161–167.[Abstract/Free Full Text]
8. de Lemos J.A., Morrow D.A. Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation (2002) 106:2868–2870.[Free Full Text]
9. Richards A.M., Nicholls M.G., Yandle T.G., Frampton C., Espiner E.A., Turner J.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation (1998) 97:1921–1929.[Abstract/Free Full Text]
10. Morrow D.A., de Lemos J.A., Sabatine M.S., Murphy S.A., Demopoulos L.A., DiBattiste P.M., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol (2003) 41:1264–1272.[Abstract/Free Full Text]
11. James S.K., Lindahl B., Siegbahn A., Stridsberg M., Venge P., Armstrong P., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation (2003) 108:275–281.[Abstract/Free Full Text]
12. Jernberg T., Stridsberg M., Venge P., Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol (2002) 40:437–445.[Abstract/Free Full Text]
13. de Lemos J.A., Morrow D.A., Bentley J.H., Omland T., Sabatine M.S., McCabe C.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 345:1014–1021.[Abstract/Free Full Text]
14. Omland T., Persson A., Ng L., O'Brien R., Karlsson T., Herlitz J., et al. N-terminal Pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation (2002) 106:2913–2918.[Abstract/Free Full Text]
15. Omland T., deLemos J.A., Morrow D.A., Antman E.M., Cannon C.P., Hall C.E.B. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. (2002) 89:463–465.[CrossRef][Web of Science][Medline]
16. Galvani M., Ottani F., Murena E., Oltrona L., Maras P., Tubaro M., et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. J Am Coll Cardiol (2003) 41:402.
17. Talwar S., Squire I.B., Downie P.F., Davies J.E., Ng L.L., Baxter G.F. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart (2000) 84:421–424.[Abstract/Free Full Text]
18. Nakao K., Mukoyama M., Hosoda K., Suga S., Ogawa Y., Saito Y., et al. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol (1991) 69:1500–1506.[Web of Science][Medline]
19. Pan J., Fukuda K., Saito M., Matsuzaki J., Kodama H., Sano M., et al. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res (1999) 84:1127–1136.[Abstract/Free Full Text]
20. Morrow D.A., de Lemos J.A., Sabatine M.S., Murphy S.A., Demopoulos L.A., DiBattiste P.M., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction. B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol (2003) 41:1264–1272.[Abstract/Free Full Text]
21. Talwar S., Squire I.B., Downie P.F., McCullough A.M., Campton M.C., Davies J.E., et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J (2000) 21:1514–1521.[Abstract/Free Full Text]
22. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., Burnett J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol (2002) 40:976–982.[Abstract/Free Full Text]
23. Jernberg T., Lindahl B., Siegbahn A., Andren B., Frostfeldt G., Lagerqvist B., et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol (2003) 42:1909–1916.[Abstract/Free Full Text]
24. Hunt P.J., Richards A.M., Nicholls M.G., Yandle T.G., Doughty R.N., Espiner E.A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) (1997) 47:287–296.[CrossRef][Medline]
25. White H.D., French J.K. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol (2003) 42:1917–1920.[Free Full Text]

CiteULike    Connotea    Del.icio.us    What's this?

This article has been cited by other articles:

				A. Hammerer-Lercher, B. Halfinger, B. Sarg, J. Mair, B. Puschendorf, A. Griesmacher, N. A. Guzman, and H. H. Lindner Analysis of Circulating Forms of proBNP and NT-proBNP in Patients with Severe Heart Failure Clin. Chem., May 1, 2008; 54(5): 858 - 865. [Abstract] [Full Text] [PDF]

				M G Nicholls, C M Frampton, and T G Yandle BNP: not just for heart failure Heart, January 1, 2008; 94(1): 6 - 7. [Full Text] [PDF]

				C. J. Boos, S. K. Soor, D. Kang, and G. Y.H. Lip Relationship between circulating endothelial cells and the predicted risk of cardiovascular events in acute coronary syndromes Eur. Heart J., May 1, 2007; 28(9): 1092 - 1101. [Abstract] [Full Text] [PDF]

				I. Ben-Dor, M. Haim, E. Rechavia, D. Murninkas, D. Harell, A. Porter, Z. Iakobishvili, A. Battler, and D. Hasdai Serum NT-proBNP Concentrations in the Early Phase Do Not Predict the Severity of Systolic or Diastolic Left Ventricular Dysfunction Among Patients With ST-Elevation Acute Myocardial Infarction Angiology, January 1, 2007; 57(6): 686 - 693. [Abstract] [PDF]

				G A Whalley, G D Gamble, and R N Doughty Restrictive diastolic filling predicts death after acute myocardial infarction: systematic review and meta-analysis of prospective studies Heart, November 1, 2006; 92(11): 1588 - 1594. [Abstract] [Full Text] [PDF]

				B. Verges, M. Zeller, J. Desgres, G. Dentan, Y. Laurent, L. Janin-Manificat, I. L'Huillier, G. Rioufol, J.-C. Beer, H. Makki, et al. High plasma N-terminal pro-brain natriuretic peptide level found in diabetic patients after myocardial infarction is associated with an increased risk of in-hospital mortality and cardiogenic shock Eur. Heart J., September 1, 2005; 26(17): 1734 - 1741. [Abstract] [Full Text] [PDF]

				C. Prontera, S. Storti, M. Emdin, C. Passino, L. Zyw, G. C. Zucchelli, and A. Clerico Comparison of a Fully Automated Immunoassay with a Point-of-Care Testing Method for B-Type Natriuretic Peptide Clin. Chem., July 1, 2005; 51(7): 1274 - 1276. [Full Text] [PDF]

				A. I. Larsen and K. Dickstein BNP in acute coronary syndromes: the heart expresses its suffering Eur. Heart J., August 1, 2004; 25(15): 1284 - 1286. [Full Text] [PDF]

This Article Abstract FREE Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Request Permissions Disclaimer Google Scholar Articles by Galvani, M. Articles by Ottani, F. Search for Related Content PubMed PubMed Citation Articles by Galvani, M. Articles by Ottani, F. Social Bookmarking          What's this?

Online ISSN 1879-0844 - Print ISSN 1388-9842

Copyright © 2010 European Society of Cardiology

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals China Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics